Liquidia rises after beating Q2 revenue estimates, reporting higher drug prescriptions

Shares of drug developer Liquidia LQDA.O rise 17.9% to $25 premarket

Co reports Q2 total revenue of $8.84 mln, compared with analysts' estimates of $4.05 mln, as per LSEG data

Co says its inhaled drug to treat blood pressure, Yuterpia, surpasses 900 patient prescriptions and 550 patient starts within 11 weeks after FDA approval

This initial demand has exceeded my own high expectations- CEO Roger Jeffs

On May 23, the U.S. FDA approved Yutrepia inhalation powder to treat adults diagnosed with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease

Co had cash and cash equivalents of $173.4 million as of June 30, 2025, compared with $176.5 million as of December 31, 2024

Up to last close, stock up 80.3% YTD